Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 9/20 | 0.55 |
| ▸ | CA12 | O43570 | 7/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12135783 | 0.80 | CA2 (0.51) | CA2CA12CYP2A6DYRK1A | |
| SCHEMBL10997201 | 0.79 | CA2 (0.46) | CA2CA12CYP2A6 | |
| SCHEMBL692366 | 0.77 | CYP2A6 (0.47) | CA2CA12CYP2A6DYRK1A | |
| SCHEMBL17955745 | 0.77 | CYP2A6 (0.47) | CA2CA12CYP2A6DYRK1A | |
| SCHEMBL3796719 | 0.77 | CYP2A6 (0.47) | CA2CA12ALDH1A1CYP2A6DYRK1A | |
| SCHEMBL9075377 | 0.77 | CA2 (0.51) | CA2CA12CYP2A6DYRK1ALMNA | |
| SCHEMBL23841198 | 0.76 | CA2 (0.45) | CA2CA12CYP2A6 | |
| SCHEMBL3793838 | 0.76 | CA2 (0.51) | CA2CA12CYP2A6DYRK1A | |
| SCHEMBL12597507 | 0.76 | CA2 (0.45) | CA2CA12ALDH1A1CYP2A6DYRK1A | |
| Hydrochloric Acid SCHEMBL27659768 | 0.75 | CYP2A6 (0.46) | CA2CA12ALDH1A1CYP2A6DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110182854-A1 | HCV PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS, INC. (US) | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110182854-A1 | HCV PROTEASE INHIBITORS | SERPINB1, CTSC, HPN | CA2 3766/4885CA12 2850/4885ALDH1A1 1802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.